Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
NCT07244263 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 26, 2026
- Completion date
- February 22, 2028
- Enrollment
- 90 (estimated)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.